Westlake Village biotech startup Arcutis Biotherapeutics, targeting dermatological diseases, launched a new clinical study of its topical drug to treat chronic hand eczema April 21 with the enrollment of its first patient. The 12-week Phase 1 study will test safety and tolerability of the product, called ARQ-252, in adult patients with hand eczema. ARQ-252 uses…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
